202 related articles for article (PubMed ID: 23724021)
1. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
Palacpac NM; Ntege E; Yeka A; Balikagala B; Suzuki N; Shirai H; Yagi M; Ito K; Fukushima W; Hirota Y; Nsereko C; Okada T; Kanoi BN; Tetsutani K; Arisue N; Itagaki S; Tougan T; Ishii KJ; Ueda S; Egwang TG; Horii T
PLoS One; 2013; 8(5):e64073. PubMed ID: 23724021
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Bougouma EC; Palacpac NMQ; Tiono AB; Nebie I; Ouédraogo A; Houard S; Yagi M; Coulibaly SA; Diarra A; Tougan T; Ouedraogo AZ; Soulama I; Arisue N; Yaro JB; D'Alessio F; Leroy O; Cousens S; Horii T; Sirima SB
Front Immunol; 2022; 13():978591. PubMed ID: 36119062
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
Tougan T; Ito K; Palacpac NM; Egwang TG; Horii T
Parasitol Int; 2016 Oct; 65(5 Pt A):455-8. PubMed ID: 27343834
[TBL] [Abstract][Full Text] [Related]
4. First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
Ezoe S; Palacpac NMQ; Tetsutani K; Yamamoto K; Okada K; Taira M; Nishida S; Hirata H; Ogata A; Yamada T; Yagi M; Edula JR; Oishi Y; Tougan T; Ishii KJ; Myoui A; Horii T
Vaccine; 2020 Oct; 38(46):7246-7257. PubMed ID: 33012605
[TBL] [Abstract][Full Text] [Related]
5. Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.
Yagi M; Palacpac NM; Ito K; Oishi Y; Itagaki S; Balikagala B; Ntege EH; Yeka A; Kanoi BN; Katuro O; Shirai H; Fukushima W; Hirota Y; Egwang TG; Horii T
Sci Rep; 2016 Oct; 6():34363. PubMed ID: 27703240
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Ouédraogo A; Bougouma EC; Palacpac NMQ; Houard S; Nebie I; Sawadogo J; Berges GD; Soulama I; Diarra A; Hien D; Ouedraogo AZ; Konaté AT; Kouanda S; Myoui A; Ezoe S; Ishii KJ; Sato T; D'Alessio F; Leroy O; Tiono AB; Cousens S; Horii T; Sirima SB
Front Immunol; 2023; 14():1267372. PubMed ID: 37908361
[TBL] [Abstract][Full Text] [Related]
7.
Tiono AB; Palacpac NMQ; Bougouma EC; Nebie I; Ouédraogo A; Houard S; Arisue N; D'Alessio F; Horii T; Sirima SB
Front Immunol; 2023; 14():1119820. PubMed ID: 36993981
[TBL] [Abstract][Full Text] [Related]
8. African-specific polymorphisms in
Arisue N; Palacpac NMQ; Ntege EH; Yeka A; Balikagala B; Kanoi BN; Bougouma EC; Tiono AB; Nebie I; Diarra A; Houard S; D'Alessio F; Leroy O; Sirima SB; Egwang TG; Horii T
Front Cell Infect Microbiol; 2022; 12():1058081. PubMed ID: 36590593
[TBL] [Abstract][Full Text] [Related]
9. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
11. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
[TBL] [Abstract][Full Text] [Related]
12. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.
Yagi M; Bang G; Tougan T; Palacpac NM; Arisue N; Aoshi T; Matsumoto Y; Ishii KJ; Egwang TG; Druilhe P; Horii T
PLoS One; 2014; 9(6):e98460. PubMed ID: 24886718
[TBL] [Abstract][Full Text] [Related]
13. [Development and application of next generation SE36 malaria vaccine formulated with a novel adjuvant: approach to travelers' vaccine].
Tougan T; Ishii KJ; Horii T
Yakugaku Zasshi; 2013; 133(11):1153-7. PubMed ID: 24189556
[TBL] [Abstract][Full Text] [Related]
14. Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.
Campo JJ; Dobaño C; Sacarlal J; Guinovart C; Mayor A; Angov E; Dutta S; Chitnis C; Macete E; Aponte JJ; Alonso PL
PLoS One; 2011; 6(10):e25779. PubMed ID: 22022448
[TBL] [Abstract][Full Text] [Related]
15. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
[TBL] [Abstract][Full Text] [Related]
16. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
17. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.
Laurens MB; Thera MA; Coulibaly D; Ouattara A; Kone AK; Guindo AB; Traore K; Traore I; Kouriba B; Diallo DA; Diarra I; Daou M; Dolo A; Tolo Y; Sissoko MS; Niangaly A; Sissoko M; Takala-Harrison S; Lyke KE; Wu Y; Blackwelder WC; Godeaux O; Vekemans J; Dubois MC; Ballou WR; Cohen J; Dube T; Soisson L; Diggs CL; House B; Bennett JW; Lanar DE; Dutta S; Heppner DG; Plowe CV; Doumbo OK
PLoS One; 2013; 8(11):e79323. PubMed ID: 24260195
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
20. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
